LT3331553T - Naujo tipo antikūnai prieš žmogaus gpvi ir jų panaudojimo būdai - Google Patents

Naujo tipo antikūnai prieš žmogaus gpvi ir jų panaudojimo būdai

Info

Publication number: LT3331553T
Authority: LT; Lithuania
Prior art keywords: methods; antibodies against; new type; against human; human gpvi
Prior art date: 2015-08-05

Application number

LTEPPCT/EP2016/068778T

Other languages

English (en)

Inventor

Philippe Billiald

Martine Jandrot-Perrus

Original Assignee

Acticor Biotech

Université Paris Cité

Université Paris XIII

Institut National De La Santé Et De La Recherche Médicale (Inserm)

Université Paris-Saclay

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-05

Filing date

2016-08-05

Publication date

2022-09-12

2016-08-05 Application filed by Acticor Biotech, Université Paris Cité, Université Paris XIII, Institut National De La Santé Et De La Recherche Médicale (Inserm), Université Paris-Saclay filed Critical Acticor Biotech

2022-09-12 Publication of LT3331553T publication Critical patent/LT3331553T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTEPPCT/EP2016/068778T 2015-08-05 2016-08-05 Naujo tipo antikūnai prieš žmogaus gpvi ir jų panaudojimo būdai LT3331553T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP15179908		2015-08-05
PCT/EP2016/068778 WO2017021539A2 (en)	2015-08-05	2016-08-05	Novel anti-human gpvi antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
LT3331553T true LT3331553T (lt)	2022-09-12

Family

ID=53836426

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/EP2016/068778T LT3331553T (lt)	2015-08-05	2016-08-05	Naujo tipo antikūnai prieš žmogaus gpvi ir jų panaudojimo būdai

Country Status (23)

Country	Link
US (2)	US10842870B2 (lt)
EP (2)	EP3331553B1 (lt)
JP (2)	JP7076082B2 (lt)
KR (1)	KR102751174B1 (lt)
CN (2)	CN108289939B (lt)
AU (1)	AU2016301969B2 (lt)
BR (1)	BR112018002382A8 (lt)
CA (1)	CA2994629A1 (lt)
CY (1)	CY1125400T1 (lt)
DK (1)	DK3331553T3 (lt)
ES (1)	ES2923677T3 (lt)
HR (1)	HRP20220910T1 (lt)
HU (1)	HUE059655T2 (lt)
IL (1)	IL257323B2 (lt)
LT (1)	LT3331553T (lt)
MX (1)	MX2018001465A (lt)
PL (1)	PL3331553T3 (lt)
PT (1)	PT3331553T (lt)
RS (1)	RS63482B1 (lt)
SI (1)	SI3331553T1 (lt)
SM (1)	SMT202200317T1 (lt)
WO (1)	WO2017021539A2 (lt)
ZA (1)	ZA201800804B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMT202200317T1 (it)	2015-08-05	2022-09-14	Inst Nat Sante Rech Med	Anticorpi anti-gpvi umana innovativi e relativi usi
US11692033B2 (en) *	2017-02-03	2023-07-04	Acticor Biotech	Inhibition of platelet aggregation using anti-human GPVI antibodies
AU2019270342A1 (en)	2018-05-16	2020-10-29	Morphosys Ag	Antibodies targeting glycoprotein VI
WO2021250026A1 (en) *	2020-06-08	2021-12-16	Acticor Biotech	Use of anti-gpvi antibodies for the treatment of acute respiratory distress syndrome
CN118043349B (zh) *	2021-06-11	2024-11-15	丰华生物有限公司	一种人源化抗人GPVI单克隆抗体Fab片段及其应用
US20250051452A1 (en)	2021-09-07	2025-02-13	Etablissement Francais Du Sang	Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
US20250154252A1 (en)	2022-02-21	2025-05-15	Acticor Biotech	Treatment of cardiovascular diseases using anti-human gpvi antibodies
EP4431526A1 (en)	2023-03-16	2024-09-18	Emfret Analytics GmbH & Co. KG	Anti-gpvi antibodies and functional fragments thereof
EP4556492A1 (en)	2023-11-14	2025-05-21	Acticor Biotech	Treatment of cardiovascular diseases using anti-human gpvi antibodies in subpopulations of subjects
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0617706B1 (en)	1991-11-25	2001-10-17	Enzon, Inc.	Multivalent antigen-binding proteins
US5753225A (en) *	1993-12-03	1998-05-19	The Regents Of The University Of California	Antibodies that mimic actions of neurotrophins
US20040001826A1 (en) *	1999-06-30	2004-01-01	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US6245527B1 (en) *	1999-06-30	2001-06-12	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en)	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
WO2001016321A1 (en) *	1999-09-01	2001-03-08	Otsuka Pharmaceutical Co., Ltd.	Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en)	2001-01-23	2002-07-24	Bernhard Dr. Nieswandt	Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
JP2005511005A (ja)	2001-07-18	2005-04-28	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	糖タンパク質ｖｉ融合タンパク質
GB0130543D0 (en)	2001-12-20	2002-02-06	Univ Cambridge Tech	Human antibodies and their use
EP1538165A1 (en) *	2003-12-03	2005-06-08	Procorde GmbH	Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
US20070071744A1 (en)	2002-06-07	2007-03-29	Gotz Munch	Agents which bind to epitopes of glycoprotein VI
GB0511590D0 (en) *	2005-06-07	2005-07-13	Procorde Gmbh	Anti-thrombotic agents
ES2389047T3 (es)	2004-04-29	2012-10-22	Otsuka Pharmaceutical Co., Ltd.	Anticuerpos específicos contra la glicoproteína VI y procedimientos de producción de estos anticuerpos
WO2006117910A1 (ja) *	2005-04-28	2006-11-09	Mochida Pharmaceutical Co., Ltd.	抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1876240B1 (en)	2005-04-28	2012-08-22	Mochida Pharmaceutical Co., Ltd.	Anti-human platelet membrane glycoprotein vi monoclonal antibody
EP1916259A1 (en) *	2006-10-26	2008-04-30	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
HUE029824T2 (en) *	2009-12-18	2017-04-28	Sanofi Sa	Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
KR101767717B1 (ko) *	2011-09-01	2017-08-11	에자이 알앤드디 매니지먼트 가부시키가이샤	항-인간 xcr1 항체
SMT202200317T1 (it)	2015-08-05	2022-09-14	Inst Nat Sante Rech Med	Anticorpi anti-gpvi umana innovativi e relativi usi

2016
- 2016-08-05 SM SM20220317T patent/SMT202200317T1/it unknown
- 2016-08-05 AU AU2016301969A patent/AU2016301969B2/en active Active
- 2016-08-05 IL IL257323A patent/IL257323B2/en unknown
- 2016-08-05 CA CA2994629A patent/CA2994629A1/en active Pending
- 2016-08-05 PL PL16750775.5T patent/PL3331553T3/pl unknown
- 2016-08-05 JP JP2018506340A patent/JP7076082B2/ja active Active
- 2016-08-05 ES ES16750775T patent/ES2923677T3/es active Active
- 2016-08-05 RS RS20220683A patent/RS63482B1/sr unknown
- 2016-08-05 HU HUE16750775A patent/HUE059655T2/hu unknown
- 2016-08-05 HR HRP20220910TT patent/HRP20220910T1/hr unknown
- 2016-08-05 DK DK16750775.5T patent/DK3331553T3/da active
- 2016-08-05 PT PT167507755T patent/PT3331553T/pt unknown
- 2016-08-05 WO PCT/EP2016/068778 patent/WO2017021539A2/en not_active Ceased
- 2016-08-05 LT LTEPPCT/EP2016/068778T patent/LT3331553T/lt unknown
- 2016-08-05 MX MX2018001465A patent/MX2018001465A/es unknown
- 2016-08-05 CN CN201680055046.0A patent/CN108289939B/zh active Active
- 2016-08-05 US US15/750,082 patent/US10842870B2/en active Active
- 2016-08-05 EP EP16750775.5A patent/EP3331553B1/en active Active
- 2016-08-05 EP EP22160888.8A patent/EP4091628A1/en not_active Withdrawn
- 2016-08-05 BR BR112018002382A patent/BR112018002382A8/pt not_active Application Discontinuation
- 2016-08-05 SI SI201631573T patent/SI3331553T1/sl unknown
- 2016-08-05 KR KR1020187006083A patent/KR102751174B1/ko active Active
- 2016-08-05 CN CN202210892269.XA patent/CN115925935A/zh active Pending
2018
- 2018-02-07 ZA ZA2018/00804A patent/ZA201800804B/en unknown
2020
- 2020-08-20 US US16/998,383 patent/US20200384106A1/en not_active Abandoned
2021
- 2021-07-15 JP JP2021116845A patent/JP7277689B2/ja active Active
2022
- 2022-07-26 CY CY20221100511T patent/CY1125400T1/el unknown

Also Published As

Publication number	Publication date
EP3331553B1 (en)	2022-06-29
HRP20220910T1 (hr)	2022-10-28
KR102751174B1 (ko)	2025-01-07
RU2018107409A3 (lt)	2020-01-30
PT3331553T (pt)	2022-07-27
AU2016301969B2 (en)	2022-10-06
MX2018001465A (es)	2019-01-31
IL257323A (en)	2018-03-29
WO2017021539A2 (en)	2017-02-09
IL257323B2 (en)	2024-01-01
HK1256816A1 (en)	2019-10-04
PL3331553T3 (pl)	2022-09-12
JP2022025033A (ja)	2022-02-09
EP3331553A2 (en)	2018-06-13
IL257323B1 (en)	2023-09-01
AU2016301969A1 (en)	2018-02-22
JP7277689B2 (ja)	2023-05-19
CN108289939A (zh)	2018-07-17
ZA201800804B (en)	2023-12-20
RS63482B1 (sr)	2022-09-30
JP2018526990A (ja)	2018-09-20
CA2994629A1 (en)	2017-02-09
BR112018002382A8 (pt)	2022-12-06
CY1125400T1 (el)	2025-05-09
HUE059655T2 (hu)	2022-12-28
WO2017021539A3 (en)	2017-03-16
US20200384106A1 (en)	2020-12-10
EP4091628A1 (en)	2022-11-23
RU2018107409A (ru)	2019-09-05
BR112018002382A2 (pt)	2019-04-16
JP7076082B2 (ja)	2022-05-27
US10842870B2 (en)	2020-11-24
CN108289939B (zh)	2022-08-12
DK3331553T3 (da)	2022-08-01
KR20180068952A (ko)	2018-06-22
CN115925935A (zh)	2023-04-07
US20180236071A1 (en)	2018-08-23
SMT202200317T1 (it)	2022-09-14
NZ739560A (en)	2024-01-26
ES2923677T3 (es)	2022-09-29
SI3331553T1 (sl)	2022-11-30

Publication	Publication Date	Title
IL279606A (en)	2021-03-01	Anti-TREM2 antibodies and methods of using them
IL262092A (en)	2018-11-29	Humanized anti-pacap antibodies and uses thereof
LT3618863T (lt)	2023-10-10	Anti-tigit antikūnai ir jų panaudojimo būdai
LT3295951T (lt)	2020-09-25	Anti-pvrig antikūnai ir naudojimo būdai
IL251970B (en)	2021-12-01	Anti-cd79b antibodies and methods of use
IL259495A (en)	2018-07-31	Antibodies and methods for using them
IL254068A0 (en)	2017-10-31	Anti-dll3 chimeric antigen receptors and methods of use
PL3353210T3 (pl)	2025-02-24	Przeciwciała anty-TIGIT i sposoby stosowania
IL254887A0 (en)	2017-12-31	Anti-sortilin antibodies and methods of using them
LT3353212T (lt)	2021-12-27	Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
LT3303396T (lt)	2023-01-10	Antikūnai prieš ox40 ir jų panaudojimo būdai
LT3333191T (lt)	2020-12-10	Anti-c10orf54 antikūnai ir jų panaudojimas
SG11201803567XA (en)	2018-05-30	Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en)	2020-02-27	Anti-trem2 antibodies and methods of use thereof
DK3215532T3 (da)	2020-01-02	Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
HUE046756T2 (hu)	2020-03-30	Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
IL254670A0 (en)	2017-11-30	Humanized anti-c1s antibodies and methods of use thereof
LT3274370T (lt)	2020-02-10	Antikūnai prieš ceacam6 ir jų panaudojimas
LT3331553T (lt)	2022-09-12	Naujo tipo antikūnai prieš žmogaus gpvi ir jų panaudojimo būdai
PT3548033T (pt)	2024-08-09	Compostos e respectivos métodos de utilização
PL3250610T3 (pl)	2024-01-29	Przeciwciała anty-FcRn i sposoby ich stosowania
LT3341027T (lt)	2024-06-25	Transfekcijos kompleksai ir jų panaudojimo būdai
LT3525583T (lt)	2025-11-10	Anti-c1s antikūnai ir jų naudojimo būdai
IL260019A (en)	2018-07-31	Antibodies targeting cd32b and methods of using them
LT3498292T (lt)	2021-11-25	Uspa2 baltymo konstruktai ir jų panaudojimas